Ab­cam brings a long­time col­lab­o­ra­tor in house as part of $340M buy­out pact

Bio­Vi­sion has sup­plied Ab­cam with re­search tools since 1999, and now the two are mak­ing it of­fi­cial as part of a merg­er un­veiled Mon­day.

Ab­cam will buy­out Bio­Vi­sion as part of a $340 mil­lion ac­qui­si­tion deal to bring aboard the sup­pli­er’s bio­chem­i­cal and cell-based as­says for bi­o­log­i­cal re­search, as well as re­com­bi­nant pro­teins, an­ti­bod­ies and en­zymes.

The deal will give Ab­cam con­trol of Bio­Vi­sion’s port­fo­lio and al­low for both the ex­pan­sion of re­search ex­ist­ing ar­eas of fo­cus such as on­col­o­gy, neu­ro­science and epi­ge­net­ics and prepa­ra­tion to ex­pand in­to new prod­ucts. As a part of the deal, Ab­cam will de­vel­op and sup­ply prod­ucts and ser­vices to NKY, the pre­vi­ous own­er of Bio­Vi­sion and re­ceive sup­port for on­go­ing de­vel­op­ment and com­mer­cial­iza­tion of in vit­ro di­ag­nos­tic prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER